Advertisement

LBA-6565

Atrial fibrillation ablation vs antiarrhythmic drugs: A multicenter randomized trial
  • Pierre Jais
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Bruno Cauchemez
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Laurent Macle
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Emile Daoud
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Albert L. Waldo
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Jeremy N. Ruskin
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Meleze Hocini
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Mark D. O’Neill
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Jacques Clementy
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
  • Michel Haissaguerre
    Affiliations
    Hopital Cardiologique Haut leveque, Bordeaux-Pessac, France, Hopital Lariboisiere, Paris, France, Institut de Cardiologie de Montreal, Montreal, PQ, Canada, Mid-Ohio cardiology, Columbus, OH, Univ Hosp of Cleveland Cardiology, Cleveland, OH, Mass General Hosp Arrhythmia service, Boston, MA
    Search for articles by this author
Published:August 02, 2006DOI:https://doi.org/10.1016/j.hrthm.2006.07.004
      Atrial fibrillation (AF) may be treated by antiarrhythmic drugs (AAD) or catheter ablation (ABL). The superiority of one strategy over the other has not been demonstrated. An independent steering committee designed and supervised a randomized multicenter (2 European, 2 North American) comparison of these treatments in pts with paroxysmal AF resistant to one or more AADs.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Heart Rhythm
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect